

**Neuroscience of Disease Forum**

**“Isocitrate Dehydrogenase Mutated Gliomas; an Update on Pathophysiology and Treatment”**

**Who:**Faculty, Graduate Students, Postdoctoral Fellows, Clinicians, Medical Students

**When:**          **Friday, March 29, 2024, 12:15-1:45 p.m. EDT**

**Where:**        AS7-2072 and Virtual Presentation via Zoom

**Zoom Link**:  Join from PC, Mac, Linux, iOS, or Android:

<https://umassmed.zoom.us/j/98463614874?pwd=TE0wam9pekdKZytJZHdsZXc3dGo4Zz09>

**Password:** 776589

**Learning objectives:**

1. To appreciate the natural history and presentation of oligodendroglioma.

2. To appreciate recent advances in the therapy of IDH-mutant gliomas, including oligodendroglioma.

3. To appreciate the role of neurons in glioma pathophysiology and emerging therapeutic strategies targeting glioma neuroscience .

**Presented by:**

****

**David Cachia, MD Michelle Monje, MD, PhD**

Associate Professor of Medicine, Milan Gambhir Professor of Pediatric Neuro-Oncology

Division of Hematology - Oncology Department of Neurology and Neurological Sciences

Director of the Neuro-oncology Program Investigator, Howard Hughes Medical Institute

University of Massachusetts Chan Stanford University

Medical School

Sponsored by the Departments of Neurology and Neurobiology and the NeuroNexus Institute

Accreditation Statement: The University of Massachusetts Chan Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement: The University of Massachusetts Chan Medical School designates this live activity for a maximum of 1 *AMA PRA Category 1 credit(s) ™*.   
Physicians should claim only credit commensurate with the extent of their participation in the activity.

Statement on Faculty Disclosure: It is the policy of the University of Massachusetts Chan Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Chan Medical School are required to present evidence-based data, identify, and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.